Grounded in human genetics
The programme starts from genetic discoveries about how the sweat gland is controlled.
A new medicine for excessive sweating.
Hidros Therapeutics International (HTI) is a Swedish biotech company developing a targeted RNA therapy for primary focal hyperhidrosis.
The condition
Hyperhidrosis affects daily life.
Primary focal hyperhidrosis is chronic, excessive sweating in defined areas of the body, such as the palms, soles, underarms or face, without an underlying disease. It is triggered by heat, stress and emotion.
For many people it has a significant impact on social life, work and wellbeing. Existing treatments each involve trade-offs in effect, convenience, cost or side effects.
- Antiperspirants
- Iontophoresis
- Botulinum toxin injections
- Microwave therapy
- Surgery
Our approach
Reducing sweat production at its source.
Sweat is produced by eccrine glands in the skin. Our programme is designed to act inside these glands, locally, in the areas where sweating causes problems.
The work builds on research in genetics at Uppsala University by our scientific founders, Professor Niklas Dahl and Joakim Klar, PhD.
A targeted RNA medicine
We are developing a small interfering RNA (siRNA) designed to reduce sweat production in the gland.
Local treatment
The therapy is intended for local use, where the patient needs it.
The company
A Swedish biotech company.
Hidros Therapeutics International is a privately held biotech company based in Uppsala, Sweden.
- Company name
- Hidros Therapeutics International AB
- Corporate ID
- 556943-1058
- Registered office
- Uppsala, Sweden
Contact
Get in touch.
For partnering, investment or other enquiries, send us a message and we will get back to you.